Bladder instillation of adriamycin in the treatment of bladder cancer.
Intravesical Adriamycin instillation was used in 10 patients with transitional cell carcinoma of the bladder as postoperative prophylactic treatment against recurrence. The protocol for bladder instillation was 20 mg/10 ml of Adriamycin twice weekly for a total of eight doses. One patient developed recurrence in 3 months and three, in 6 months. The main local side-effects were frequency and dysuria which occurred in four cases. Leukopenia and increased SGOT and SGPT values each occurred in one case. No cases of cardiotoxicity, fibrosis, or atrophy of the bladder mucosa were found. Further studies are necessary to achieve the best possible results.
D000855:Anorexia / Q000139:chemically induced; D001402:B-Lymphocytes / Q000276:immunology; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008111:Liver Function Tests; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D013601:T-Lymphocytes / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery
D004317:Doxorubicin